How do you know if your alliance or business partnership is operating effectively? Sure, revenue is a gauge, as well as hitting key development milestones. It still doesn’t tell you if the partners are productively leveraging the resources available to the alliance, or if it is operating in an environment built on mutual trust and respect, focused on innovating and producing results.

Alliances are inherently inefficient and it is the job of the alliance professionals managing the alliance to preserve and enhance the value intended when entering into the collaboration, while identifying and mitigatin

In 2016, former US President Jimmy Carter announced that he no longer required treatment for his metastatic melanoma that had spread to his brain and liver. After six months of being treated with the immunotherapy pembrolizumab (trade name KEYTRUDA), together with surgery and radiation therapy, doctors had seen no sign of his disease for three months. This was a remarkable development—before pembrolizumab was approved in 2011, President Carter’s cancer likely would have been fatal.

Known as a “checkpoint inhibitor” pembrolizumab and other drugs in its class work—in simplest terms—by turbocharging the body’s immune system so that it can fight cancer. Its success, and the success of other similar drugs, such as avelumab (trade name BAVENCIO), and nivolumab (trade name OPDIVO), have unleashed a tsunami of clinical collaborations to identify how using these drugs in combination might expand and extend their significant patient benefits—and maximize their value to the biopharma companies that are de...

Jan Twombly, president of The Rhythm of Business is joined by Judy Baselice, director, alliance management at Pfizer and Ellen Locker, executive director, alliance management Merck & Co. at the 2018 ASAP Biopharma Conference in an interactive discussion about the complex web of agreements, restrictions, and obligations resulting from the explosion of clinical collaborations to create combination therapies....